report cover

Global and United States Urological Cancer Therapeutics Drugs Market Report & Forecast 2022-2028

  • 22 September 2022
  • Life Sciences
  • 115 Pages
  • Report code : 24WT-7376916

Urological Cancer Therapeutics Drugs Market

1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Global Urological Cancer Therapeutics Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Urological Cancer Therapeutics Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume for the Year 2017-2028
1.3 United States Urological Cancer Therapeutics Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Urological Cancer Therapeutics Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume for the Year 2017-2028
1.4 Urological Cancer Therapeutics Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Urological Cancer Therapeutics Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Urological Cancer Therapeutics Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Urological Cancer Therapeutics Drugs Market Dynamics
1.5.1 Urological Cancer Therapeutics Drugs Industry Trends
1.5.2 Urological Cancer Therapeutics Drugs Market Drivers
1.5.3 Urological Cancer Therapeutics Drugs Market Challenges
1.5.4 Urological Cancer Therapeutics Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Urological Cancer Therapeutics Drugs Market Segment by Type
2.1.1 Xofigo (radium Ra 223 dichloride)
2.1.2 Jevtana (cabazitaxel)
2.1.3 Inlyta (axitinib)
2.1.4 Votrient (pazopanib hydrochloride)
2.1.5 Sutent (sunitinib malate)
2.1.6 Zytiga (abiraterone acetate)
2.1.7 Xtandi (enzalutamide)
2.1.8 Opdivo (nivolumab)
2.1.9 Provenge (sipuleucel-T)
2.2 Global Urological Cancer Therapeutics Drugs Market Size by Type
2.2.1 Global Urological Cancer Therapeutics Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Urological Cancer Therapeutics Drugs Market Size by Type
2.3.1 United States Urological Cancer Therapeutics Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Urological Cancer Therapeutics Drugs Market Segment by Application
3.1.1 Hospital
3.1.2 Medical Research Laboratory
3.1.3 Others
3.2 Global Urological Cancer Therapeutics Drugs Market Size by Application
3.2.1 Global Urological Cancer Therapeutics Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Urological Cancer Therapeutics Drugs Market Size by Application
3.3.1 United States Urological Cancer Therapeutics Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Urological Cancer Therapeutics Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Company
4.1 Global Urological Cancer Therapeutics Drugs Market Size by Company
4.1.1 Top Global Urological Cancer Therapeutics Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Urological Cancer Therapeutics Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022)
4.2 Global Urological Cancer Therapeutics Drugs Concentration Ratio (CR)
4.2.1 Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Urological Cancer Therapeutics Drugs in 2021
4.2.3 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Urological Cancer Therapeutics Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Urological Cancer Therapeutics Drugs Market Size by Company
4.5.1 Top Urological Cancer Therapeutics Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Urological Cancer Therapeutics Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Urological Cancer Therapeutics Drugs Sales by Players (2020, 2021 & 2022)
5 Global Urological Cancer Therapeutics Drugs Market Size by Region
5.1 Global Urological Cancer Therapeutics Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Urological Cancer Therapeutics Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Urological Cancer Therapeutics Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Urological Cancer Therapeutics Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Urological Cancer Therapeutics Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Urological Cancer Therapeutics Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporation Information
7.3.2 Johnson & Johnson Description and Business Overview
7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
7.3.5 Johnson & Johnson Recent Development
7.4 AstraZeneca
7.4.1 AstraZeneca Corporation Information
7.4.2 AstraZeneca Description and Business Overview
7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
7.4.5 AstraZeneca Recent Development
7.5 Astellas
7.5.1 Astellas Corporation Information
7.5.2 Astellas Description and Business Overview
7.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
7.5.5 Astellas Recent Development
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporation Information
7.6.2 Bristol-Myers Squibb Description and Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
7.6.5 Bristol-Myers Squibb Recent Development
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Corporation Information
7.7.2 Abbott Laboratories Description and Business Overview
7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
7.7.5 Abbott Laboratories Recent Development
7.8 Celgene Corporation
7.8.1 Celgene Corporation Corporation Information
7.8.2 Celgene Corporation Description and Business Overview
7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
7.8.5 Celgene Corporation Recent Development
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Corporation Information
7.9.2 Dendreon Corporation Description and Business Overview
7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
7.9.5 Dendreon Corporation Recent Development
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Corporation Information
7.10.2 Ferring Pharmaceuticals Description and Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
7.10.5 Ferring Pharmaceuticals Recent Development
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc Corporation Information
7.11.2 GlaxoSmithKline plc Description and Business Overview
7.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products Offered
7.11.5 GlaxoSmithKline plc Recent Development
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Corporation Information
7.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Indevus Pharmaceuticals Inc Products Offered
7.12.5 Indevus Pharmaceuticals Inc Recent Development
7.13 Ipsen
7.13.1 Ipsen Corporation Information
7.13.2 Ipsen Description and Business Overview
7.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Ipsen Products Offered
7.13.5 Ipsen Recent Development
7.14 Roche Healthcare
7.14.1 Roche Healthcare Corporation Information
7.14.2 Roche Healthcare Description and Business Overview
7.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Roche Healthcare Products Offered
7.14.5 Roche Healthcare Recent Development
7.15 Sanofi S.A.
7.15.1 Sanofi S.A. Corporation Information
7.15.2 Sanofi S.A. Description and Business Overview
7.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Sanofi S.A. Products Offered
7.15.5 Sanofi S.A. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Urological Cancer Therapeutics Drugs Industry Chain Analysis
8.2 Urological Cancer Therapeutics Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Urological Cancer Therapeutics Drugs Distributors
8.3 Urological Cancer Therapeutics Drugs Production Mode & Process
8.4 Urological Cancer Therapeutics Drugs Sales and Marketing
8.4.1 Urological Cancer Therapeutics Drugs Sales Channels
8.4.2 Urological Cancer Therapeutics Drugs Distributors
8.5 Urological Cancer Therapeutics Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Ask Our Expert

Leave This Empty:

*Required Information
List of Tables
Table 1. Urological Cancer Therapeutics Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Urological Cancer Therapeutics Drugs Market Trends
Table 3. Urological Cancer Therapeutics Drugs Market Drivers
Table 4. Urological Cancer Therapeutics Drugs Market Challenges
Table 5. Urological Cancer Therapeutics Drugs Market Restraints
Table 6. Global Urological Cancer Therapeutics Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Urological Cancer Therapeutics Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Urological Cancer Therapeutics Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Urological Cancer Therapeutics Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Urological Cancer Therapeutics Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Urological Cancer Therapeutics Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Urological Cancer Therapeutics Drugs Sales by Manufacturer, (K MT), 2017-2022
Table 14. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022) & (USD/MT)
Table 16. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2021)
Table 18. Top Players of Urological Cancer Therapeutics Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 20. Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Urological Cancer Therapeutics Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Urological Cancer Therapeutics Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Urological Cancer Therapeutics Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Urological Cancer Therapeutics Drugs Sales by Players, (K MT), 2020, 2021 & 2022
Table 26. United States Urological Cancer Therapeutics Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Urological Cancer Therapeutics Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Urological Cancer Therapeutics Drugs Sales in Volume by Region (2017-2022) & (K MT)
Table 29. Global Urological Cancer Therapeutics Drugs Sales in Volume Forecast by Region (2023-2028) & (K MT)
Table 30. Global Urological Cancer Therapeutics Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Urological Cancer Therapeutics Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
Table 33. North America Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Urological Cancer Therapeutics Drugs Sales in Volume by Region (2017-2028) & (K MT)
Table 35. Asia Pacific Urological Cancer Therapeutics Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
Table 37. Europe Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
Table 39. Latin Americaa Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
Table 41. Middle East and Africa Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Novartis Corporation Information
Table 43. Novartis Description and Business Overview
Table 44. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 45. Novartis Urological Cancer Therapeutics Drugs Product
Table 46. Novartis Recent Development
Table 47. Pfizer Corporation Information
Table 48. Pfizer Description and Business Overview
Table 49. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 50. Pfizer Product
Table 51. Pfizer Recent Development
Table 52. Johnson & Johnson Corporation Information
Table 53. Johnson & Johnson Description and Business Overview
Table 54. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 55. Johnson & Johnson Product
Table 56. Johnson & Johnson Recent Development
Table 57. AstraZeneca Corporation Information
Table 58. AstraZeneca Description and Business Overview
Table 59. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 60. AstraZeneca Product
Table 61. AstraZeneca Recent Development
Table 62. Astellas Corporation Information
Table 63. Astellas Description and Business Overview
Table 64. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 65. Astellas Product
Table 66. Astellas Recent Development
Table 67. Bristol-Myers Squibb Corporation Information
Table 68. Bristol-Myers Squibb Description and Business Overview
Table 69. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 70. Bristol-Myers Squibb Product
Table 71. Bristol-Myers Squibb Recent Development
Table 72. Abbott Laboratories Corporation Information
Table 73. Abbott Laboratories Description and Business Overview
Table 74. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 75. Abbott Laboratories Product
Table 76. Abbott Laboratories Recent Development
Table 77. Celgene Corporation Corporation Information
Table 78. Celgene Corporation Description and Business Overview
Table 79. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 80. Celgene Corporation Product
Table 81. Celgene Corporation Recent Development
Table 82. Dendreon Corporation Corporation Information
Table 83. Dendreon Corporation Description and Business Overview
Table 84. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 85. Dendreon Corporation Product
Table 86. Dendreon Corporation Recent Development
Table 87. Ferring Pharmaceuticals Corporation Information
Table 88. Ferring Pharmaceuticals Description and Business Overview
Table 89. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 90. Ferring Pharmaceuticals Product
Table 91. Ferring Pharmaceuticals Recent Development
Table 92. GlaxoSmithKline plc Corporation Information
Table 93. GlaxoSmithKline plc Description and Business Overview
Table 94. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 95. GlaxoSmithKline plc Product
Table 96. GlaxoSmithKline plc Recent Development
Table 97. Indevus Pharmaceuticals Inc Corporation Information
Table 98. Indevus Pharmaceuticals Inc Description and Business Overview
Table 99. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 100. Indevus Pharmaceuticals Inc Product
Table 101. Indevus Pharmaceuticals Inc Recent Development
Table 102. Ipsen Corporation Information
Table 103. Ipsen Description and Business Overview
Table 104. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 105. Ipsen Product
Table 106. Ipsen Recent Development
Table 107. Roche Healthcare Corporation Information
Table 108. Roche Healthcare Description and Business Overview
Table 109. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 110. Roche Healthcare Product
Table 111. Roche Healthcare Recent Development
Table 112. Sanofi S.A. Corporation Information
Table 113. Sanofi S.A. Description and Business Overview
Table 114. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 115. Sanofi S.A. Product
Table 116. Sanofi S.A. Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Urological Cancer Therapeutics Drugs Customers List
Table 120. Urological Cancer Therapeutics Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Urological Cancer Therapeutics Drugs Product Picture
Figure 2. Global Urological Cancer Therapeutics Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Urological Cancer Therapeutics Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Urological Cancer Therapeutics Drugs Sales 2017-2028 (K MT)
Figure 5. United States Urological Cancer Therapeutics Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Urological Cancer Therapeutics Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Urological Cancer Therapeutics Drugs Sales 2017-2028 (K MT)
Figure 8. United States Urological Cancer Therapeutics Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Urological Cancer Therapeutics Drugs Market Share in Global, in Volume (K MT) 2017-2028
Figure 10. Urological Cancer Therapeutics Drugs Report Years Considered
Figure 11. Product Picture of Xofigo (radium Ra 223 dichloride)
Figure 12. Product Picture of Jevtana (cabazitaxel)
Figure 13. Product Picture of Inlyta (axitinib)
Figure 14. Product Picture of Votrient (pazopanib hydrochloride)
Figure 15. Product Picture of Sutent (sunitinib malate)
Figure 16. Product Picture of Zytiga (abiraterone acetate)
Figure 17. Product Picture of Xtandi (enzalutamide)
Figure 18. Product Picture of Opdivo (nivolumab)
Figure 19. Product Picture of Provenge (sipuleucel-T)
Figure 20. Global Urological Cancer Therapeutics Drugs Market Share by Type in 2022 & 2028
Figure 21. Global Urological Cancer Therapeutics Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. Global Urological Cancer Therapeutics Drugs Sales Market Share in Value by Type (2017-2028)
Figure 23. Global Urological Cancer Therapeutics Drugs Sales by Type (2017-2028) & (K MT)
Figure 24. Global Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 25. Global Urological Cancer Therapeutics Drugs Price by Type (2017-2028) & (USD/MT)
Figure 26. United States Urological Cancer Therapeutics Drugs Market Share by Type in 2022 & 2028
Figure 27. United States Urological Cancer Therapeutics Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 28. United States Urological Cancer Therapeutics Drugs Sales Market Share in Value by Type (2017-2028)
Figure 29. United States Urological Cancer Therapeutics Drugs Sales by Type (2017-2028) & (K MT)
Figure 30. United States Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 31. United States Urological Cancer Therapeutics Drugs Price by Type (2017-2028) & (USD/MT)
Figure 32. Product Picture of Hospital
Figure 33. Product Picture of Medical Research Laboratory
Figure 34. Product Picture of Others
Figure 35. Global Urological Cancer Therapeutics Drugs Market Share by Application in 2022 & 2028
Figure 36. Global Urological Cancer Therapeutics Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 37. Global Urological Cancer Therapeutics Drugs Sales Market Share in Value by Application (2017-2028)
Figure 38. Global Urological Cancer Therapeutics Drugs Sales by Application (2017-2028) & (K MT)
Figure 39. Global Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 40. Global Urological Cancer Therapeutics Drugs Price by Application (2017-2028) & (USD/MT)
Figure 41. United States Urological Cancer Therapeutics Drugs Market Share by Application in 2022 & 2028
Figure 42. United States Urological Cancer Therapeutics Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 43. United States Urological Cancer Therapeutics Drugs Sales Market Share in Value by Application (2017-2028)
Figure 44. United States Urological Cancer Therapeutics Drugs Sales by Application (2017-2028) & (K MT)
Figure 45. United States Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 46. United States Urological Cancer Therapeutics Drugs Price by Application (2017-2028) & (USD/MT)
Figure 47. North America Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 48. North America Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 49. U.S. Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Canada Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Europe Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 52. Europe Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 53. Germany Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. France Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. U.K. Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Italy Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Russia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Asia-Pacific Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 59. Asia-Pacific Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 60. China Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Japan Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. South Korea Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. India Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Australia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. China Taiwan Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Indonesia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Thailand Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Malaysia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Latin America Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 70. Latin America Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 71. Mexico Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Brazil Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Argentina Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Middle East & Africa Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 75. Middle East & Africa Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 76. Turkey Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 77. Saudi Arabia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 78. UAE Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 79. Urological Cancer Therapeutics Drugs Value Chain
Figure 80. Urological Cancer Therapeutics Drugs Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SAMPLE REPORT INCLUDES
  • Industry Market SizeIndustry Market Size
  • SWOT AnalysisSWOT Analysis
  • Industry Major PlayersIndustry Major Players
  • Revenue ForecastsRevenue Forecasts
  • Historical and Forecast GrowthHistorical and Forecast Growth
  • Profitability AnalysisProfitability Analysis
SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Urological Cancer Therapeutics Drugs Market

Leave This Empty: